T cell lineage acute lymphoblastic leukemia (ALL) is characterized by immunophenotypic and molecular high diversity. T-ALL represents 15% of pediatric and 25% of adult newly diagnosed ALL cases [1]. In frontline therapy, all patients with T-ALL are treated with similar multiagent chemotherapy regimens...
Acute myeloid leukemia (AML) is preceded by malignant clonal expansion of progenitor cells with impaired differentiation and is associated with the highest proportion of deaths among all types of leukemia [1, 2, 3–4]. In the United States, in 2024, there were 20,800 new cases of AML, accounting...
Multiple myeloma (MM) is a malignant hematologic neoplasia characterized by bone marrow infiltration of monoclonal plasma cells. The secreted functionless monoclonal immunoglobulins or light chains can be detected as the M-protein and clonally increased light chains in serum and/or urine [1, 2]. MM remains...
Previous results from CASSIOPEIA (NCT02541383) demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance versus observation...
AML Classifications: WHO vs ICC 2022 Update The following is a summary of the article “Definitions of Acute Myeloid Leukaemia and their clinical significance according to the WHO 2022 and ICC classification” by Donata Backhaus et al (University of Leipzig Medical Center, Germany), which...